Comparative bioavailability study of cefixime (equivalence to 100 mg/5 ml) suspension (Winex vs Suprax) in healthy male volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 43, Issue 10, 2005, Pages 499-504

  Asiri, Y A ^a   Al Said, M S ^a   Al Khamis, K I ^a   Niazy, E M ^a   El Sayed, Y M ^a   Al Rashood, K A ^a   Al Yamani, M J ^a   Alsarra, I A ^a   Al Balla, S A ^b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Cefixime; Comparative bioavailability; Healthy volunteers; Suprax; Winex

Indexed keywords

CEFIXIME; WINEX;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CALCULATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SAUDI ARABIA; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; STUDENT T TEST; SUSPENSION; VOLUNTEER;

EID: 26844481203     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP43499     Document Type: Article

References (15)

1. Asiri YA, Niazy EM, El-Sayed YM, Al-Khamis KI, Alsarra IA 2004 Rapid and sensitive high performance liquid chromatography method for the determination of cefixime in human plasma. Saudi Pharm J in preparation
2. DRUGDEX System 2004 Product Information: Suprax, cefixime. Lederle Laboratories, Pearl River, NY, 1997. DRUGDEX System, MICROMEDIX Inc., Engelwood, CO, USA
3. Faulkner RD, Fernandez P, Lawrence G, Sia LL, Falkowski AJ 1988 Absolute bioavailability of cefixime in man. J Clin Pharmacol 28: 700-706
4. Faulkner RD, Sia LL, Barone JS, Forbes SJ, Silber BM 1989 Bioequivalency of oral suspension formulations of cefixime. Biopharm Drug Dispos 10: 205-211
5. Food and Drug Administration (FDA) 2001 Gaudiness for industry: Bioanalytical method validation. Center for Drug Evaluation and Research (CDER), Rockville, MD, USA
6. Jones RN 1988 Antimicrobial activity, spectrum and pharmacokinetics of old and new orally administered cephems. Antimicrob Newsl 5: 1-7
7. Hauschke D, Steinijans VW, Diletti E, Burk M 1992 Sample size determination for bioequivalence assessment using a multiplicative model. J Pharmacokinet Biopharm 20: 557-561
8. Micromedex Inc 2002 Thomdon Micromedex, Version 4.0. Greenwood Village, CO, USA
9. Montay G, Masala F, Le Roux Y, Le Biboux A, Uhlrich J, Chassard D, Thebault JJ, Roche G, Frydman A 1991 Comparative bioavailability study of cefixime administered as tablets or aqueous solution. Drugs 4: 6-9
10. Nix DE, Symonds WT, Hyatt JM, Wilton JH, Teal MA, Reidenberg P, Affrime MB 1997 Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime acetyl in healthy volunteers. Pharmacotherapy 17: 121-125
11. SAS Institute Inc 1990 SAS/STAT User's guide, Version 6.0 (4th ed, vol. 2). Cary, NC, USA
12. Schall R, Luus H 1992 Comparison of absorption rates in bioequivalence studies of immediate release drug formulations. Int J Clin Pharmacol Ther Toxicol 17: 2231-2341
13. Steinijans VW, Diletti E 1983 Statistical analysis of bioavailability studies; parametric and non-parametric confidence intervals. Eur J Clin Pharmacol 24: 127-136
14. Schuirmann DJ 1987 A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 15: 657-680
15. Westlake WF 1972 Use of confidence intervals in analysis of comparative bioavailability trials. J Pharm Sci 61: 1340-1341